Blue Rabbit Vets Hop for Powerful Drug Import Approval
Published Date: 12/1/2025
Notice
Summary
Blue Rabbit Veterinary LLC wants to become an official importer of two strong veterinary drugs, Etorphine HCI and Thiafentanil, both Schedule II controlled substances. This means vets and animal care pros might get easier access to these important medicines soon. People and companies can share their thoughts or objections online by December 31, 2025, so don’t miss the deadline!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Importer applied to supply zoo/wildlife drugs
On October 28, 2025, Blue Rabbit Veterinary LLC applied to be registered to import Etorphine HCI (code 9059) and Thiafentanil (code 9729), both Schedule II controlled substances. If approved, the company plans to import those drugs in final dosage form for distribution to prospective zoo and wildlife customers.
Registration limited; commercial sale barred
The registration application is limited to the listed import activity and expressly states no other activities for these drug codes are authorized. The authorization will not extend to the import of FDA-approved or non‑approved finished dosage forms for commercial sale.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-21718 — Center for Scientific Review; Notice of Closed Meeting
The NIH’s Center for Scientific Review is holding a secret virtual meeting on December 19, 2025, to review important grant applications for research training. This meeting was delayed by a government shutdown but is now urgent to keep funding on track for key health projects. Researchers waiting on NIH money should pay attention because these reviews help decide who gets funded next.
Next: 2025-21720 — Bulk Manufacturer of Controlled Substances Application: Benuvia Operations, LLC
Benuvia Operations, LLC wants to become a big-time maker of some powerful drugs like LSD and codeine for research and making new medicine doses. If you have thoughts or concerns, you’ve got until January 30, 2026, to speak up or ask for a hearing. This move could speed up drug research but doesn’t change any sales or money rules right now.